In 1999, a trial firstly proved the clinical benefit of adding etanercept, a tumor necrosis factor inhibitor (TNFi), to methotrexate in Rheumatoid Arthritis (RA) patients who did not respond to the standard of care [1]. This evidence concerns the gene TNF and rheumatoid arthritis.